Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, affects gastric emptying by slowing the movement of food through the stomach
This protects you from financing medication you might not continue using
Many advanced research programs run comparative studies using both compounds to observe dual versus triple receptor agonism differences within identical experimental conditions
It is the easiest to access for self-injection
Volume: ~0.17 mL with an insulin syringe (29-31 gauge) Timing: Once weekly, same day each week in most reported protocols IM injection community sources do not describe IM protocols, citing concern over faster absorption Reconstitution Quick Reference The following reflects dilution ratios documented in community reconstitution sources: Math: 3 mg / 2 mL = 1.5 mg/mL = 1,500 mcg/mL
Compounded medications are regulated at the state level under less intensive oversight, reducing compliance costs